New and existing investors provided crossover financing for the synthetic biology technology developer, which already counts Merck & Co, AGC Asahi Glass and JSR Life Sciences as investors.
AbSci, a US-based synthetic biology technology developer backed by corporates Merck & Co, AGC Asahi Glass and JSR Life Sciences, raised $125m in crossover financing on Tuesday.
Casdin Capital and Redmile Group co-led the round investing alongside financial services and investment group Fidelity, D1 Capital Partners, Perceptive Advisors, aMoon Edge, Irving Investors and existing backers including ArrowMark Partners.
Founded in 2011, AbSci provides drug discovery and cell line development services for biopharmaceutical companies. Its technology platforms can produce proteins and…
